Q2 Earnings Forecast for ProKidney Issued By HC Wainwright

ProKidney Corp. (NASDAQ:PROK) – Stock analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of ProKidney in a research note issued on Thursday, March 19th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.13) for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for ProKidney’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for ProKidney’s Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.66) EPS, FY2028 earnings at ($0.57) EPS and FY2029 earnings at ($0.34) EPS.

ProKidney (NASDAQ:PROK) last posted its quarterly earnings data on Wednesday, March 18th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.00 million.

A number of other analysts also recently issued reports on the stock. Jefferies Financial Group upgraded shares of ProKidney to a “strong-buy” rating in a report on Wednesday, March 18th. Wall Street Zen cut shares of ProKidney from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProKidney in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.40.

ProKidney Stock Performance

NASDAQ PROK opened at $1.93 on Monday. ProKidney has a 52 week low of $0.46 and a 52 week high of $7.13. The stock’s 50 day moving average price is $2.15 and its two-hundred day moving average price is $2.43. The stock has a market capitalization of $580.60 million, a price-to-earnings ratio of -3.71 and a beta of 1.75.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PROK. State Street Corp raised its stake in shares of ProKidney by 1.1% during the 4th quarter. State Street Corp now owns 480,345 shares of the company’s stock worth $1,076,000 after purchasing an additional 5,388 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of ProKidney by 2.0% in the fourth quarter. Squarepoint Ops LLC now owns 351,421 shares of the company’s stock valued at $787,000 after buying an additional 6,845 shares in the last quarter. Zullo Investment Group Inc. bought a new position in shares of ProKidney in the third quarter valued at $28,000. Cetera Investment Advisers acquired a new position in ProKidney during the fourth quarter worth $28,000. Finally, ExodusPoint Capital Management LP increased its holdings in ProKidney by 22.8% during the fourth quarter. ExodusPoint Capital Management LP now owns 128,853 shares of the company’s stock worth $289,000 after buying an additional 23,924 shares during the last quarter. Institutional investors and hedge funds own 51.59% of the company’s stock.

Key ProKidney News

Here are the key news stories impacting ProKidney this week:

• Positive Sentiment: Jefferies upgraded ProKidney, providing an immediate bullish catalyst from a well-known bank that can attract buying interest and coverage. Read More.
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintains a $12 price target while publishing quarter-by-quarter EPS forecasts (Q1–Q4 2026 and multi‑year estimates). The continued Buy stance and a high target provide a longer-term bullish narrative for investors focused on upside potential. Read More.
• Neutral Sentiment: Market consensus across eight covering firms is a “Moderate Buy” (mixed mix of buys, holds and sells). That consensus supports modest positive sentiment but shows notable analyst divergence (including two sell ratings). Read More.
• Negative Sentiment: HC Wainwright lowered several future EPS forecasts (FY2026–FY2029) in its update, trimming near- and medium‑term profitability expectations — a headwind for valuation and nearer-term sentiment despite the maintained Buy rating. Read More.
• Negative Sentiment: Wall Street Zen lowered its rating on PROK, which adds to negative headline risk and may pressure short-term flows from sentiment-driven investors. Read More.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.